X4 Pharmaceuticals Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, everyone. My name's Adam Craig. I'm the Executive Chairman of X4, a Boston-based biotech company specializing in rare hematology. First, I'd like to thank Jefferies for the invitation to be here today. It's a pleasure to be back in this room after several years. I will be making some forward-looking statements today. I'll refer you to the text in this slide. X4 is focused on maximizing the potential of CXCR4 antagonism with our lead compound, mavorixafor, which we're studying in the rare hematologic condition, primary chronic neutropenia. Over the last couple of years, X4 has undergone a lot of corporate change with restructuring, with new management, and we've now got to the point where we're very close to finishing enrollment on our pivotal phase III trial, the 4WARD trial, in primary chronic neutropenia.
If we complete enrollment by the end of this year, we expect to have data in the first quarter of 2028. CXCR4 antagonism is a very simple concept, but the CXCR4 is responsible for the migration of neutrophils from the bone marrow into the bloodstream. If you antagonize that target, the bone marrow releases neutrophils into the bloodstream. It's this concept that we believe will lead to an infection benefit, a decrease in infection in patients on our 4WARD trial, patients who have very low ANCs when they come on trial, and I'll explain that in a little bit. Patients with primary chronic neutropenia represent an unmet medical need. They live difficult lives. They have multiple infections, they have difficulty socializing, and currently, the only available therapy is available antibiotics to treat the infections and prophylactic antibiotics to decrease infections, and G-CSF.
As many of you know, G-CSF is an injection, and it can be uncomfortable to give injections. It can cause bone pain. Patients have fatigue. One of the most striking things you'll see from the data I'll present to you shortly is many patients with primary chronic neutropenia are young, and they don't want to be on G-CSF for decades because there is a risk of malignant transformation to MDS and potentially AML. This graphic here just basically illustrates that the lower your ANC, the higher the risk of infection. If you look on the left-hand column, what you'll see is we describe severe and moderate ANC, moderate being an ANC less than 1,000, severe being less than 500.
If I got a syringe out and took blood from you all now, most people in this room would have an ANC over 1,500, and that would afford you protection against infection on a day-to-day basis. That's not the case for the primary chronic neutropenia, particularly the moderate and severe disease patients. They are at high risk of infection in day-to-day life. The kind of infections they get can be widespread. They can get chest infections, sinus infections. They can get boils under the skin, abscesses. It's all over. The life of a primary chronic neutropenia can be very limited because the concerns about going out into the world and getting infections. There is a desire for a new therapy, and when we talk to patients and we ask them, "What do you want?" They want their lives back.
They want to live a life where they're not so restricted. It's almost like during COVID where people didn't go out because they were concerned about infection. It's that kind of scenario. The one thing they do want is an oral therapy, which I'll go into in detail. At the moment, they've got antibiotics, which can cause toxicity, as we know, can cause problems with long-term resistance, or they've got injections with G-CSF. Neither of those options are ideal. If we can move forward and get mavorixafor approved, we'll have an oral therapy in this setting, and I think that will be quite groundbreaking. Our clinical program currently involves two trials. The first trial, one phase III and one phase II. What led us to conducting these trials was a small phase II that was conducted in 23 patients, where we basically looked at two things.
We looked at, can mavorixafor increase the ANC in patients who have low ANCs? The other side of the question was, if you are maintaining a decent ANC on G-CSF, can you reduce the G-CSF dose or potentially remove G-CSF and still maintain a decent ANC? They're the two things we tested in this 23-patient trial. As you can see on the left, you'll see the baseline characteristics of the 23, and then on the right, you'll see that 10 were monotherapy and 13 patients had received G-CSF. Quite simply, if you start with the monotherapy patients who had low ANCs, we can see over a three, six-month period that normal ANCs can be maintained when mavorixafor is introduced, and in this case, over 1,500 or more, which is the normal level. Remember, some of these patients have ANCs of 500.
Most of them are less than 1,000 before they start the trial. The next question we asked was, as I said, can we reduce the G-CSF dose? Because one of the attractions of mavorixafor is that we could potentially replace some of the use of G-CSF in the marketplace or reduce its use, which with the bone pain, the discomfort, infections, risk of malignancy would be an advantage for patients. We found in this small study, and we're going to test it a bit further, and I'll explain in a few minutes, but we found in this trial that about 70% of G-CSF dosing was reduced, and in a number of patients, we were able to eliminate G-CSF completely. That's quite a significant finding, considering that G-CSF was approved 30 years ago and has really been the primary treatment for these patients.
From a toxicity point of view, this drug is well tolerated. We do get some GI toxicity in the first few weeks of therapy. It can be treated with over-the-counter medication, and we're finding in the current trial, this really is not a problem because we've learned as a company how to manage it, and as long as patients are informed in advance they could get some GI toxicity and they should take drugs like loperamide if they have anti-diarrheals, we found that this has not been a great concern. This is our phase III 4WARD trial, the trial it's referring to. This will, if successful, will be part of an sNDA application for primary chronic neutropenia. We already have for mavorixafor an approval for ultra-rare condition called WHIM, which is a form of severe neutropenia, but this is for a broader population.
It's a double-blinded placebo-controlled trial where we look at reduction in infection and increase ANC as the co-primary endpoints over a 12-month period. That's why if we complete enrollment as we expect to by the end of this year, we will have a one-year follow-up and then data in the early part of 2028. The two endpoints are well powered for a sample size of 126. The reduction in infection, it's an estimate, it's powered for at least a 30% reduction in infection, and that's 89% power. Then the ANC, which is an increase of ANC of 500 cells per microliter on at least three occasions over that 12-month period, that's again about a 30% increase in ANC, and that's 93% powering.
We've been asked consistently by investors how we're doing, and obviously the data is blinded, but we did think it was useful recently, our investor day two or three weeks ago, to share some data and give you an idea of the kind of patients we're getting. I already mentioned to you that many primary chronic neutropenia patients are young, and you can see here the median age coming on this study is 36 years, pretty young population. About 37% of patients are on G-CSF, so they're randomized on the study between mavorixafor plus or minus G-CSF, and then placebo plus or minus G-CSF. In the G-CSF randomization, there's 37% of patients. The median ANC on trial is 583, which puts the median in the severe bracket. Remember, it's 500 or less to be defined as severe primary chronic neutropenia. That's important. The FDA, prior to the join, we joined as a management team, the FDA communicated the company, it's very important that we enroll a population in whom we can show a difference.
I'm pleased to see that we are enrolling patients who have ANC, a median ANC of 583. Then finally, along the same line, 68% of patients have three or more infections. Get on the trial, you need two infections in the prior 12 months. If we have patients who are actually having more than that, again, we have a sick population in which we can show a difference. One of the limitations of the 4WARD trial, and we've always recognized it, is the 4WARD trial, you can't change your G-CSF dose. The FDA wanted us to fix the dose of G-CSF throughout the whole study.
One of the things that will be missing the first day for the reps, unless we fill that gap, is some communication, some data on how you change the G-CSF dose if you start mavorixafor and you eventually want to potentially get off G-CSF. So, my apologies. What we designed was the 4STEPS trial, brilliantly named by one of our team, because it involves patients going on G-CSF plus mavorixafor, an eight-week run-in period, and then a period where over 24 weeks, where patients can reduce the dose, physicians can reduce their patients' dose of G-CSF by 25% in four steps.
The idea of this trial is to show that once mavorixafor is initiated, you can reduce the G-CSF, and ideally keep a patient at the end of it on an oral therapy with relatively low toxicity, and remove the need for the painful, unpleasant G-CSF injections. The data for that, the trial is due to start, enroll the first patient early next year, and we would expect the primary data to be out in the first quarter of 2028. If you ask physicians what do they want here, and if we did a survey of physicians, in the footnotes you can see who we spoke to, community and academic physicians, and asked them, is the profile of mavorixafor attractive? It confirms what we believe. They want to see something that is differentiated from G-CSF. They want something that is an oral therapy.
The data we received back from the survey was they will prescribe it if we are successful, and that is what we thought. We thought this market is primed for a new therapy, particularly an oral therapy. How many patients are there? Probably the commonest question we get from investors after, "How is the study powered?" The answer is, it depends on the label. If we have a label that fits exactly to the study, which is patients have to have two or more infections before coming on mavorixafor, we think there are 15,000 patients. If the label just says symptomatic patients, as it does for the NEUPOGEN label, then the potential market is double, up to 30,000 patients. That is out of an overall primary chronic neutropenia population of 95,000 patients, which you see at the bottom here, for patients over the age of 12.
You can see that we really, for a small company in Boston with less than 50 employees, the potential here for the company is really quite substantial, and the potential to do good for a lot of patients is there. Quick corporate overview from a cash perspective. We had last reported $187 million in cash. We have 144 million shares outstanding. Many of them are held in this room. To finish off, we are a company, a small company that has gone under a lot of change recently, but we are now primarily focused on completing the 4WARD trial with the new C-suite, with the right investors, and with the aim of getting a second approval in chronic neutropenia. Our cash runway will go into 2029.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
1 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
